PBAC Public Summary Documents – September 2021
Page last updated: 14 January 2022
Public Summary Documents relating to the September 2021 PBAC meeting.
- Dapagliflozin (chronic kidney disease): Tablet 10 mg; Forxiga® - September 2021
- Dapagliflozin (heart failure): Tablet 10 mg; Forxiga®
- Methoxsalen: Solution for blood fraction 20 microgram per mL, 10 mL; Uvadex®
- Nintedanib: Capsule 100 mg, Capsule 150 mg; Ofev®
- Onasemnogene abeparvovec: Solution for injection, customised based on patient weight; Zolgensma®
- Tafamidis: Capsule 61 mg; Vyndamax®
